Treatment of Acute Nonlymphoblastic Leukemia in Childhood: Results of protocol ANLL-827 and ANLL-861 studies

DOI Web Site PubMed 1 Citations
  • YANAI Masanori
    Department of Pediatrics, Nagasaki University School of Medicine/Children's Cancer and Leukemia Study Group
  • TSUJI Yoshio
    Department of Pediatrics, Nagasaki University School of Medicine/Children's Cancer and Leukemia Study Group
  • TAKEDA Takeo
    Department of Pediatrics, National Sapporo Hospital/Children's Cancer and Leukemia Study Group
  • OKA Toshiaki
    Department of Pediatrics, Asahikawa Medical College/Children's Cancer and Leukemia Study Group
  • YATABE Michio
    Department of Pediatrics, Akita University School of Medicine/Children's Cancer and Leukemia Study Group
  • KIKUTA Atushi
    Department of Pediatrics, Fukushima Medical College/Children's Cancer and Leukemia Study Group
  • KANEKO Yasuhiko
    Department of Pediatrics, Saitama Cancer Center/Children's Cancer and Leukemia Study Group
  • SEKINE Isao
    Department of Pediatrics, Dokkyo Medical College/Children's Cancer and Leukemia Study Group
  • MATSUSHITA Takeji
    Department of Pediatrics, National Medical Center of Hospital/Children's Cancer and Leukemia Study Group
  • UTSUMI Jiro
    Department of Pediatrics, Niigata Cancer Center/Children's Cancer and Leukemia Study Group
  • SHIKE Shoichiro
    Department of Pediatrics, Kanazawa Medical College/Children's Cancer and Leukemia Study Group
  • KOIZUMI Shoichi
    Department of Pediatrics, Kanazawa University School of Medicine/Children's Cancer and Leukemia Study Group
  • NAKAMURA Kanji
    Pediatric Section, Fukui Red Cross Hospital/Children's Cancer and Leukemia Study Group
  • MIMAYA Junichi
    Division of Hematology/Oncology, Shizuoka Children's Hospital/Children's Cancer and Leukemia Study Group
  • OHTA Shigeru
    Departmest of Pediatrics, Shiga Medical College/Children's Cancer and Leukemia Study Group
  • TANAKA Kiyoshi
    Department of Pediatrics, Tottori University School of Medicine/Children's Cancer and Leukemia Study Group
  • KOMAZAWA Masaru
    Division of Hematology, Okayama Children's Medical Center/Children's Cancer and Leukemia Study Group
  • KADOYA Shoichiro
    Pediatric Section, Yamaguchi Red Cross Hospital/Children's Cancer and Leukemia Study Group
  • NINOMIYA Tsuneo
    Department of Pediatrics, Tokushima Medical College/Children's Cancer and Leukemia Study Group
  • SHIRAHATA Satoshi
    Department of Pediatrics, Sangyo Medical College/Children's Cancer and Leukemia Study Group
  • HIYOSHI Yasuhiko
    Department of Pediatrics, Kurume Usiversity School of Medicine/Children's Cancer and Leukemia Study Group
  • KAWAKAMI Kiyoshi
    Department of Pediatrics, Kagoshima University School of Medicine/Children's Cancer and Leukemia Study Group
  • NISHI Kunihiro
    Clinical Laboratory Section, Kyushu Cancer Center National Hospital/Children's Cancer and Leukemia Study Group
  • FUJIMOTO Takeo
    Department of Pediatrics, Aichi Medical College/Children's Cancer and Leukemia Study Group

Bibliographic Information

Other Title
  • 小児急性非リンパ性白血病の治療研究
  • 小児急性非リンパ性白血病の治療研究--ANLL-827およびANLL-861プロトコールの治療成績
  • ショウニ キュウセイ ヒ リンパセイ ハッケツビョウ ノ チリョウ ケンキュウ
  • ANLL-827およびANLL-861プロトコールの治療成績

Search this article

Abstract

Sixty-five evaluable children with acute nonlymphoblastic leukemia (FAB categoies: M1, M2, M4, M5) entered into the protocol studies of Children's Cancer and Leukemia Study Group (CCLSG) between February, 1981 and December, 1985. Before October, 1984, 49 cases were treated with protocol ANLL-827; Regimen-I (neo-MINI-COAAP therapy) or Regimen-II (BH-AC DMP therapy). After November 1984, 16 cases were treated with a new protocol ANLL-861 (combined therapy of Regimen-I and II). Three protocol regimens with multi-drug chemotherapy were administered for three years, without aggressive CNS prophylaxis.<br>Fifty of 65 children (76.9%) achieved complete remission (CR). There was no difference in CR rate among three protocol-regimens. The rates of cotinuous complete remission (CCR) at 20 months were 40.5%, 18.8%, and 72.7%, respectively in Regimen-I, Regimen-II, and ANLL-861. However, statistically there was no difference in CCR rate among the protocol-regimens. The median duration of CCR was 11.2 months and 18.8 months in Regimen-I and II. Seven patients have been off chemotherapy, and 6 cases of them have remained in CCR. The incidence of CNS involvement with the three protocol-regimens was 9.2% (6/65). A high incidence of CNS involvement occurred in patients with M4 and M5. CR duration in patients with monocytic leukemia (M4, M5) was significantly shorter (P<0.01) than that in patients with M1 or M2.<br>These results indicate that current treatment regimens improve prognosis for acute nonlymphoblastic leukemia in childhood.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 28 (10), 1754-1762, 1987

    The Japanese Society of Hematology

Citations (1)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top